Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health intends to negotiate a sole source contract with Biolegend for custom oligos required for single cell copy number analysis. This acquisition supports clinical quality control assays for CAR-T cell products. Interested parties may submit capability statements by May 8, 2026.
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Biolegend.
Acquisition Description:
Custom Oligios needed by PACT team at CCE to do single cell copy number analysis with Tapestri instrument for CAR-T cell products to support clinical QC assay.
The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-26-004813) by 12:00 PM eastern standard time on 05/08/2026 to: valerie.gregorio@nih.gov.
All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
INTENT TO SOLE SOURCE - BIOLEGEND OLIOGOS is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.